New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:35 EDTLPTNLpath's Lpathomab for traumatic brain injury receives $1.7M development grant
Lpath received official notification from the National Institutes of Neurological Diseases and Stroke that it has been awarded a $1.7M, 2.5-year grant to develop its antibody therapeutic, Lpathomab against the bioactive lipid lysophosphatidic acid for the treatment of traumatic brain injury. The Phase l amount of $224K will fund studies designed to repeat in rats the efficacy previously demonstrated in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5M will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.
News For LPTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
16:08 EDTLPTNLpath names Gary Atkinson as interim CEO
Lpath (LPTN) announced that Gary Atkinson has been appointed interim CEO of Lpath, effective immediately. Atkinson will continue to serve as Lpath's CFO. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer (PFE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use